Unites companies from healthcare and life sciences
Velsera at a glance
Velsera is a consolidation of three leading companies within digital diagnostics, bioinformatics, healthcare data and advanced analytics enabling better healthcare, diagnostics, and precision medicine. It unites Seven Bridges, Pierian and UgenTec to advance and accelerate the work of both domains. All companies remain actively engaged with existing customers, enhance current offerings, accelerate new offerings, and bring integrated solutions to market as leading providers of global omics and insights.
- Year acquired
- 2022
- Revenue
- EUR 36m
- Location
- Boston
- Employees
- 428
- Website
- https://www.velsera.com
- Investment theme
- Changing Demographics
- Contact
- tommi.unkuri@summaequity.com
- SDG alignment
3
What are the challenges Velsera addresses
-
97%
of global healthcare data generated annually goes unused in siloed systems and clinical workflows, hindering advancement of AI in the secto
-
90%
of clinical drug development fails
How does Velsera help?
-
Reality today
Medicine moves too slow. The rapid pace of innovation in technology is not translating into acceleration of precision medicine. Too much time is wasted de-siloing and harmonizing multi-omic data, rather than analyzing and deriving insights.
-
Velsera approach
Velsera bridges the gap between clinical and discovery by solving fundamental challenges in data assembly and reporting. The company provides integrated software and expert services to transform the dry lab workflow, enabling seamless multi-omic data identification, ingestion, secure patient data management, and analysis.
-
Aspirational future
A connected data ecosystem revealing the true promise of precision medicine — a continuous flow of knowledge between researchers, scientists, and clinicians around the world, creating insights that radically improve human health.
-
Who is impacted?
Velsera empowers clinical diagnostic labs, next-generation sequencing assay and equipment manufacturers, biotech and pharma, and non-profit/government agencies to make breakthroughs in precision medicine—ultimately improving patient outcomes.
-
Contribution
Velsera drives R&D productivity and patient outcomes by accelerating innovation, improving workforce efficiency, and reducing cost of data and technology—helping to get the right medicine, to the right patient, in the fastest possible time.
-
Risks to impact
This is a nascent and emerging space with constantly changing customer, competitor, and regulatory dynamics. Velsera is developing differentiated multi-omic capabilities and expertise to navigate the complex global environment and scale impact quickly .